Telix Pharmaceuticals welcomes Dr David Cade to the team

Company News

by Rachael Jones

Telix Pharmaceuticals (ASX:TLX) today announced that Dr. David Cade has joined the Telix executive leadership team in the role of Chief Business Officer and Head of Investor Relations.

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR), has

David brings over 20 years of significant commercial, clinical and public company experience to Telix. Notable prior executive roles include Chief Medical Officer at Cochlear and Sirtex, where his responsibilities included not only clinical strategy but also commercial and investorfacing aspects.

Shares in Telix Pharmaceuticals (ASX:TLX) closed 0.75 per cent higher on Friday.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.